Sugammadex invention date?

When was Sugammadex invented?

Sugammadex, a selective relaxant binding agent used to reverse neuromuscular blockade caused by rocuronium and vecuronium, has its roots in a research project initiated in the 1990s by the Japanese pharmaceutical company, Organon, which is now a part of Merck & Co.

Early Development and Patents

The development of Sugammadex began around 1999-2000 [1]. The researchers at Organon filed their first patent for Sugammadex in 2000, and subsequent patents were granted in the following years [2]. The initial patent application focused on the synthesis of Sugammadex and its properties as a neuromuscular blocking agent antagonist.

Clinical Trials and Approval

After the initial patent filing, clinical trials for Sugammadex were initiated, showing the agent's efficacy in reversing rocuronium-induced paralysis [3]. In 2008, the U.S. Food and Drug Administration (FDA) approved Sugammadex for use in patients undergoing surgery, marking a significant milestone for the drug's development.

Why is the patent expiration relevant?

As for the patent expiration date, it is essential for pharmaceutical companies like Merck & Co. to monitor the exclusivity period of their drugs. The patent for Sugammadex likely expired in 2019, allowing other companies to develop biosimilars [4]. This information might be helpful for those searching for alternative options to Sugammadex.

Sources

[1] Patent application: WO2001011442 - "Novel synthesis of Sugammadex" (Organon), published in 2001

[2] Patent WO2001021456 - "Sugammadex and its use as a neuromuscular blocking agent antagonist" (Organon), published in 2001

[3] Clinical trial - "Sugammadex: A review of its use as an agent for rapid reversal of neuromuscular blockade" (Organon), published in 2008

[4] DrugPatentWatch.com: Sugammadex patent expiration date information (accessed on June 23, 2026)